Skip to main content
. Author manuscript; available in PMC: 2013 Jul 15.
Published in final edited form as: Anticancer Res. 2011 Nov;31(11):3673–3681.

Figure 6.

Figure 6

Knocking down AKT sensitizes ovarian cancer cells to CDDO-Me. A: OVCAR-5 and MDAH 2774 cells were transfected with siRNA-AKT or scrambled siRNA sequence for 48 h and levels of AKT were measured by Western blotting. The sensitivity of control and transfected cells to low concentrations of CDDO-Me was determined at 72 h by MTS assay. Similar results were obtained in two independent experiments. B: Cellular lysates of OVCAR-5 and MDAH 2774 cells treated with CDDO-Me as described were analyzed by Western blotting for BCL-2, BCL-xL, cIAP, survivin and β-actin (loading control). Bar graphs reflect change in signal strength compared to the control. Similar results were obtained in two independent experiments. *p<0.05 compared to control and non-targeting siRNA transfected cells.